Gennova Biopharmaceuticals Ltd (GBL), the Pune-based biotechnology company working on the nation’s first mRNA-based Covid-19 vaccine submitted the interim clinical data of the Phase-I study to the Central Drugs Standard Control Organisation (CDSCO), the union government’s National Regulatory Authority (NRA).

Vaccine Subject Expert Committee (SEC) reviewed the interim phase-I data and found that HGCO19 was safe, tolerable, and immunogenic in the participants of the study, the Union Ministry of Science & Technology said.
https://ehealth.eletsonline.com/2021/08/indias-first-mrna-covid-19-...